N@N

Amarillo Biosciences, Inc.: Amarillo Biosciences Announces Influenza Study in Australia Well Underway With 60 Subjects Randomiz

^{Published on 2009-05-29 04:13:44, Last Modified on 2009-05-29 04:14:37 - Market Wire}
 

AMARILLO, TX--(Marketwire - May 29, 2009) - Amarillo Biosciences, Inc. (AMAR) (OTCBB: [ AMAR ]) today announced that 60 healthy adult volunteers out of a target of 160 have been enrolled to date in a clinical study of the company's oral interferon product. This Phase 2 clinical trial at the University of Western Australia is being conducted by Dr. Manfred Beilharz and colleagues. The study is expected to show that lozenges containing a low dose of interferon-alpha can prevent infection or reduce the severity of infection with influenza and other common respiratory viruses when taken once a day during a typical winter cold/flu season.

Dr. Joseph Cummins, President, CEO of AMAR, said, "Unlike antiviral drugs that act directly against influenza, which can lead to viral resistance, AMAR's oral interferon product works indirectly by boosting the immune system, making the development of viral resistance highly unlikely. This ongoing study is an important step in proving that our low-dose interferon lozenges can be a safe and effective alternative to antiviral drugs for influenza." Dr. Cummins added, "Our human studies continue to build on the published work by Dr. Beilharz (Biochemical and Biophysical Research Communications 355:740-744, 2007), which shows that low dose oral interferon can prevent death in mice infected with mouse-adapted H1N1 influenza virus."

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 7% of Amarillo Biosciences shares and has provided over $18 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including influenza, hepatitis C, chronic cough, and opportunistic infections in patients who are HIV positive. In its 25-year history, the Company has invested nearly $40 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the web site at [ http://www.amarbio.com/ ].

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" and "Item 7A. Qualitative and Quantitative Disclosures About Market Risk" of the Company's Form 10-K for the fiscal year ended December 31, 2008.